THE AUTHORS REPLY

Mohammad Ehsanul Karim¹, Paul Gustafson², John Petkau², Helen Tremlett^{3

4}

Affiliations

¹ Centre for Health Evaluation and Outcome Sciences (CHÉOS), St. Paul's Hospital, Vancouver, BC, Canada.
² Department of Statistics, Faculty of Science, University of British Columbia, Vancouver, BC, Canada.
³ Division of Neurology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
⁴ Brain Research Centre, University of British Columbia, Vancouver, BC, Canada.

Comment

Mohammad Ehsanul Karim et al. Am J Epidemiol. 2016.

. 2016 Dec 1;184(11):857-858.

doi: 10.1093/aje/kww158. Epub 2016 Nov 16.

Mohammad Ehsanul Karim¹, Paul Gustafson², John Petkau², Helen Tremlett^{3

4}

¹ Centre for Health Evaluation and Outcome Sciences (CHÉOS), St. Paul's Hospital, Vancouver, BC, Canada.
² Department of Statistics, Faculty of Science, University of British Columbia, Vancouver, BC, Canada.
³ Division of Neurology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
⁴ Brain Research Centre, University of British Columbia, Vancouver, BC, Canada.

No abstract available

Comment on

Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.
Karim ME, Gustafson P, Petkau J, Tremlett H; Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group. Karim ME, et al. Am J Epidemiol. 2016 Aug 15;184(4):325-35. doi: 10.1093/aje/kwv445. Epub 2016 Jul 25. Am J Epidemiol. 2016. PMID: 27455963 Free PMC article.
RE: "COMPARISON OF STATISTICAL APPROACHES FOR DEALING WITH IMMORTAL TIME BIAS IN DRUG EFFECTIVENESS STUDIES".
Wolkewitz M, Beyersmann J, Ohneberg K, Schumacher M. Wolkewitz M, et al. Am J Epidemiol. 2016 Dec 1;184(11):856-858. doi: 10.1093/aje/kww156. Epub 2016 Nov 16. Am J Epidemiol. 2016. PMID: 27852601 No abstract available.